Last €9.96 EUR
Change Today -0.04 / -0.40%
Volume 6.5K
ROVI On Other Exchanges
Symbol
Exchange
Berlin
Continuous
As of 11:38 AM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

laboratorios farmaceuticos r (ROVI) Snapshot

Open
€9.91
Previous Close
€10.00
Day High
€10.00
Day Low
€9.75
52 Week High
01/21/14 - €10.23
52 Week Low
10/17/14 - €7.90
Market Cap
498.0M
Average Volume 10 Days
68.2K
EPS TTM
€0.48
Shares Outstanding
50.0M
EX-Date
07/3/14
P/E TM
20.8x
Dividend
€0.16
Dividend Yield
1.62%
Current Stock Chart for LABORATORIOS FARMACEUTICOS R (ROVI)

Related News

No related news articles were found.

laboratorios farmaceuticos r (ROVI) Related Businessweek News

No Related Businessweek News Found

laboratorios farmaceuticos r (ROVI) Details

Laboratorios Farmacéuticos ROVI, S.A. engages in the research, development, in licensing, manufacturing, and marketing of small molecule and specialty biologic drugs in Spain and internationally. Its principal product includes Bemiparin, a low molecular weight heparin. The company’s prescription products comprise Hibor to prevent thromboembolic disease; Osseor to treat post-menopausal osteoporosis; Hepadren for the prevention of clotting in the extracorporeal circuit; Pneumovax-23, a vaccine for immunization against pneumococcal illness; Glufan for relieving symptoms of degenerative osteoarthritis; and Corlentor for treating chronic stable angina pectoris. Its prescription products also include Exxiv for relieving the symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylarthritis, and acute gouty arthritis; Calcio y Vitamina D3 ROVI to treat osteoporosis; Bertanel to treat adults active rheumatoid, juvenile idiopatic, and psoriatic arthritis; Vytorin for patients with primary hypercholesterolaemia or mixed hyperlipidaemia; Absorcol for patients with hypercholesterolaemia and phytosterolaemia; and Thymanax for treating depressive episodes in adults. In addition, the company offers diagnostic products, such as SonoVue contrast medium for use with ultrasound imaging; and Iopamiro and Iomeron contrast media for diagnosis by computed tomography; and Multihance And Prohance for use in diagnostic magnetic resonance imaging, as well as OTC products comprising Perspirex to control sweating from the armpits; Enerzone, a protein product; Dentimelo to repair oral mucosal lesions and gums; and ColdPack cold and hot bag for reliving pain. Further, it distributes products licensed from other laboratories. The company was founded in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmacéuticos ROVI, S.A. is a subsidiary of Inversiones Clidia, S.L.

Founded in 1946

laboratorios farmaceuticos r (ROVI) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €410.0K
Chairman of The Board, Chief Executive Office...
Total Annual Compensation: €244.0K
Chief Financial Officer, Director and Member ...
Total Annual Compensation: €305.0K
Director of Corporate Development and Directo...
Total Annual Compensation: €303.0K
Compensation as of Fiscal Year 2013.

laboratorios farmaceuticos r (ROVI) Key Developments

Laboratorios Farmaceuticos ROVI, S.A. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 12:20 PM

Laboratorios Farmaceuticos ROVI, S.A. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 12:20 PM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom.

Laboratorios Farmaceuticos ROVI, S.A. to Report Nine Months, 2014 Results on Nov 06, 2014

Laboratorios Farmaceuticos ROVI, S.A. announced that they will report nine months, 2014 results on Nov 06, 2014

Laboratorios Farmaceuticos ROVI, S.A. Announces Consolidated Earnings Results for the Nine Months Ended September 30, 2014; Provides Operating Revenue Guidance for the Full Year of 2014 and 2015

Laboratorios Farmaceuticos ROVI, S.A. announced consolidated earnings results for the nine months ended September 30, 2014. For the period, the company reported revenue of EUR 173,292,000 compared to EUR 160,927,000 a year ago, mainly driven by the strength of the prescription-based pharmaceutical business, where sales rose 9%, clearly outperforming the market, and by the toll manufacturing business which grew by 6%. Operating profit was EUR 22,403,000 compared to EUR 20,454,000 a year ago. Profit before income tax was EUR 20,956,000 compared to EUR 19,471,000 a year ago. Profit for the period was EUR 19,863,000 compared to EUR 18,676,000 a year ago. Net cash generated from operating activities was EUR 17,012,000 compared to EUR 16,755,000 a year ago. Purchases of intangible assets were EUR 1,849,000 compared to EUR 5,974,000 a year ago. Purchases of property, plant and equipment were EUR 10,377,000 compared to EUR 6,836,000 a year ago. EBITDA increased by 14% to EUR 28.9 million compared to the same period of the previous year. For 2014, the company expects a mid-to-high single digit growth rate for the operating revenue. The company expects operating revenue to grow from mid to high single digit for the full year 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ROVI:SM €9.96 EUR -0.04

ROVI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ROVI.
View Industry Companies
 

Industry Analysis

ROVI

Industry Average

Valuation ROVI Industry Range
Price/Earnings 20.0x
Price/Sales 2.1x
Price/Book 3.1x
Price/Cash Flow 14.8x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LABORATORIOS FARMACEUTICOS R, please visit www.rovi.es. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.